Supplier
Optum Medical Care of New Jersey PC
Optum Medical Care of New Jersey PC was paid $218.82M by Medicaid between Jan 2018 and Dec 2024, across 448 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 30% of everything it billed.
33Billing provider infoOPTUM MEDICAL CARE OF NEW JERSEY PC
SECAUCUS, NJ 07094
SECAUCUS, NJ 07094
33aNPI1578665048assigned 09/03/2006
33bProvider typeDurable Medical Equipment & Medical Supplies
28Total paid$218.82M
24GClaims4,314,959
24DCodes billed448
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Durable Medical Equipment & Medical Supplies providers in New Jersey
Rank by total paid#2 of 302
Median peer was paid$689.07
This provider vs. median317,556×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 444,913 | $22.16M | |
| 2019 | 526,234 | $22.66M | |
| 2020 | 587,564 | $30.43M | |
| 2021 | 642,507 | $39.37M | |
| 2022 | 854,032 | $42.78M | |
| 2023 | 734,968 | $37.02M | |
| 2024incomplete | 524,741 | $24.39M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 30% | 809,661 | 744,476 | $65.18M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 25% | 919,464 | 836,730 | $54.13M |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 2.8% | 47,667 | 45,935 | $6.11M |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | 2.6% | 216,337 | 209,491 | $5.77M |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 2.3% | 51,110 | 50,429 | $4.95M |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 2.2% | 110,385 | 104,828 | $4.74M |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 2.0% | 46,099 | 45,400 | $4.46M |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.9% | 25,657 | 24,366 | $4.06M |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 1.7% | 43,330 | 41,837 | $3.74M |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 1.7% | 34,757 | 34,234 | $3.65M |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 1.3% | 31,753 | 30,844 | $2.80M |
| L3000 | Foot, insert, removable, molded to patient model, 'ucb' type, berkeley shell, each | 1.2% | 12,470 | 5,908 | $2.60M |
436 more codes
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | 1.1% | 24,340 | $2.48M |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | 1.1% | 22,536 | $2.41M |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 1.1% | 224,152 | $2.40M |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 1.1% | 64,999 | $2.38M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.1% | 8,517 | $2.37M |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 3,845 | $2.15M |
| 99244 | Office or other outpatient consultation, moderate to high complexity | <1% | 12,848 | $2.12M |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 6,699 | $2.04M |
| 92552 | <1% | 59,990 | $1.73M | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 123,096 | $1.65M |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 6,391 | $1.63M |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 5,060 | $1.46M |
| 93970 | <1% | 8,805 | $1.30M | |
| 90461 | <1% | 55,435 | $1.23M | |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 35,827 | $1.04M |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 16,121 | $953K |
| 99243 | <1% | 8,239 | $905K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 9,268 | $872K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 62,582 | $840K |
| 93000 | <1% | 69,847 | $837K | |
| 90833 | Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) | <1% | 16,920 | $830K |
| 36465 | <1% | 705 | $799K | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 88,666 | $772K |
| 93229 | <1% | 1,517 | $747K | |
| 27447 | <1% | 989 | $629K | |
| 93015 | <1% | 9,322 | $623K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 1,739 | $596K |
| 95004 | Percutaneous tests with allergenic extracts, immediate type reaction | <1% | 5,616 | $588K |
| 20610 | <1% | 10,870 | $554K | |
| 95806 | <1% | 3,761 | $516K | |
| 73620 | <1% | 25,083 | $496K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 25,943 | $484K |
| 92588 | <1% | 18,558 | $467K | |
| 36475 | <1% | 294 | $430K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 21,907 | $426K |
| 93880 | <1% | 3,009 | $420K | |
| 93925 | <1% | 2,683 | $419K | |
| 95782 | <1% | 438 | $418K | |
| 95165 | Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy, multiple dose vials | <1% | 1,349 | $418K |
| 31231 | <1% | 2,254 | $418K | |
| 95811 | <1% | 797 | $390K | |
| 29540 | <1% | 17,762 | $378K | |
| 96127 | <1% | 72,642 | $330K | |
| 90686 | <1% | 42,095 | $306K | |
| 98941 | Chiropractic manipulative treatment; spinal, 3-4 regions | <1% | 9,944 | $302K |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 4,635 | $271K |
| 92004 | Ophthalmological services: medical examination and evaluation, comprehensive, new patient | <1% | 9,840 | $265K |
| J7323 | Hyaluronan or derivative, euflexxa, for intra-articular injection, per dose | <1% | 2,302 | $247K |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 2,769 | $226K |
| 90674 | <1% | 15,321 | $223K | |
| 90746 | <1% | 4,361 | $217K | |
| 92250 | <1% | 5,713 | $213K | |
| 94060 | <1% | 4,578 | $212K | |
| 94729 | <1% | 4,853 | $209K | |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 3,873 | $206K |
| 99188 | <1% | 12,370 | $202K | |
| 73564 | <1% | 4,937 | $195K | |
| 92551 | <1% | 25,778 | $189K | |
| 17110 | <1% | 2,360 | $189K | |
| 93971 | <1% | 1,821 | $187K | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 1,354 | $184K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 761 | $180K |
| 90651 | <1% | 5,933 | $180K | |
| 31575 | <1% | 1,880 | $174K | |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 3,687 | $173K |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 3,719 | $172K |
| 95930 | <1% | 1,728 | $171K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 12,236 | $162K |
| 95117 | <1% | 16,871 | $162K | |
| 94727 | <1% | 4,855 | $160K | |
| 97161 | <1% | 3,606 | $150K | |
| 99205 | Prolong outpt/office vis | <1% | 918 | $150K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 2,380 | $138K |
| 99385 | <1% | 1,223 | $137K | |
| 93268 | <1% | 625 | $135K | |
| 99460 | <1% | 1,871 | $133K | |
| 99174 | <1% | 15,408 | $127K | |
| 69210 | <1% | 3,917 | $126K | |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 2,999 | $113K |
| 36466 | <1% | 78 | $113K | |
| 11900 | <1% | 2,877 | $111K | |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | <1% | 9,417 | $110K |
| 92567 | <1% | 8,550 | $105K | |
| 99223 | Prolong inpt eval add15 m | <1% | 1,515 | $104K |
| 90670 | <1% | 9,386 | $104K | |
| 11901 | <1% | 2,037 | $98K | |
| 90715 | <1% | 4,012 | $97K | |
| 93923 | <1% | 1,552 | $96K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 5,328 | $87K |
| 92557 | <1% | 3,687 | $87K | |
| 20611 | <1% | 1,307 | $85K | |
| 73630 | <1% | 3,555 | $80K | |
| 99245 | <1% | 418 | $79K | |
| 94010 | <1% | 2,970 | $78K | |
| 99386 | <1% | 599 | $78K | |
| 90750 | <1% | 616 | $72K | |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 3,245 | $70K |
| 0012A | <1% | 2,491 | $69K | |
| 64483 | <1% | 430 | $69K | |
| 73562 | <1% | 2,150 | $66K | |
| 99309 | Subsequent nursing facility care, per day, low to moderate complexity | <1% | 3,661 | $63K |
| 73030 | <1% | 2,111 | $63K | |
| 90619 | <1% | 2,311 | $61K | |
| 92225 | <1% | 1,394 | $61K | |
| 83655 | <1% | 6,091 | $58K | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 15,936 | $57K |
| 92012 | Ophthalmological services: medical examination and evaluation, intermediate, established patient | <1% | 1,756 | $57K |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 15,585 | $54K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 2,624 | $53K |
| 99173 | <1% | 50,914 | $51K | |
| 92550 | <1% | 4,102 | $51K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,987 | $48K |
| 0011A | <1% | 2,704 | $48K | |
| 0071A | <1% | 1,194 | $46K | |
| 10060 | <1% | 505 | $44K | |
| 98940 | <1% | 1,850 | $41K | |
| 92136 | <1% | 912 | $40K | |
| 99308 | Subsequent nursing facility care, per day, straightforward | <1% | 2,308 | $39K |
| 94618 | <1% | 1,434 | $38K | |
| 95012 | <1% | 2,199 | $37K | |
| 11301 | <1% | 355 | $37K | |
| 10061 | <1% | 257 | $36K | |
| 99442 | <1% | 1,113 | $36K | |
| 11306 | <1% | 247 | $35K | |
| 92579 | <1% | 966 | $35K | |
| 96401 | <1% | 543 | $34K | |
| G0444 | Annual depression screening, 5 to 15 minutes | <1% | 3,126 | $34K |
| 90621 | <1% | 1,347 | $34K | |
| 72100 | <1% | 1,165 | $33K | |
| 99443 | <1% | 973 | $33K | |
| 0072A | <1% | 828 | $33K | |
| 73600 | <1% | 1,481 | $32K | |
| 99441 | <1% | 1,755 | $31K | |
| 72114 | <1% | 445 | $31K | |
| 99397 | <1% | 749 | $31K | |
| 97164 | <1% | 1,093 | $28K | |
| 36416 | <1% | 6,201 | $28K | |
| 90734 | <1% | 1,606 | $28K | |
| 99462 | <1% | 861 | $28K | |
| 90682 | <1% | 627 | $28K | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 2,222 | $28K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 239 | $27K |
| 94664 | <1% | 2,573 | $27K | |
| 92587 | <1% | 1,572 | $27K | |
| 90677 | <1% | 2,557 | $27K | |
| 93228 | <1% | 1,476 | $25K | |
| 73610 | <1% | 1,011 | $25K | |
| 93458 | <1% | 114 | $25K | |
| 86580 | <1% | 3,709 | $25K | |
| 72110 | <1% | 475 | $24K | |
| 29515 | <1% | 426 | $24K | |
| G0447 | Face-to-face behavioral counseling for obesity, 15 minutes | <1% | 1,307 | $24K |
| 93298 | <1% | 1,430 | $23K | |
| 73521 | <1% | 622 | $22K | |
| 76857 | <1% | 770 | $22K | |
| 94375 | <1% | 648 | $21K | |
| 93922 | <1% | 289 | $21K | |
| 11721 | <1% | 2,188 | $21K | |
| 96112 | <1% | 232 | $20K | |
| 99401 | <1% | 1,916 | $20K | |
| 0064A | <1% | 636 | $20K | |
| 99220 | <1% | 254 | $19K | |
| 62323 | <1% | 167 | $19K | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 383 | $18K |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results | <1% | 1,653 | $17K |
| 90698 | <1% | 5,309 | $17K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 4,641 | $16K |
| 76775 | <1% | 361 | $16K | |
| 93296 | <1% | 1,499 | $16K | |
| J1439 | Injection, ferric carboxymaltose, 1 mg | <1% | 22 | $15K |
| 72275 | <1% | 535 | $15K | |
| 66761 | <1% | 80 | $15K | |
| 92134 | <1% | 657 | $15K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 455 | $14K |
| 92558 | <1% | 1,777 | $14K | |
| 96101 | <1% | 263 | $14K | |
| 64493 | <1% | 138 | $14K | |
| L4360 | Walking boot, pneumatic and/or vacuum, with or without joints, with or without interface material, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise | <1% | 83 | $13K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 72 | $13K |
| 99348 | <1% | 685 | $13K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 188 | $12K |
| 73560 | <1% | 454 | $12K | |
| 11750 | <1% | 85 | $12K | |
| 90662 | <1% | 1,988 | $12K | |
| 98942 | <1% | 260 | $12K | |
| 92340 | Fitting of spectacles, except for aphakia; monofocal | <1% | 721 | $12K |
| 85018 | <1% | 5,768 | $11K | |
| 93297 | <1% | 788 | $11K | |
| 0001A | <1% | 395 | $10K | |
| 90633 | <1% | 4,406 | $10K | |
| 0002A | <1% | 283 | $10K | |
| 11102 | <1% | 131 | $9K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 383 | $9K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 3,087 | $9K |
| 20605 | <1% | 266 | $9K | |
| 93294 | <1% | 823 | $9K | |
| 92025 | <1% | 348 | $8K | |
| 90836 | <1% | 143 | $8K | |
| J0153 | Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | <1% | 3,197 | $8K |
| 57454 | <1% | 62 | $8K | |
| 95115 | <1% | 930 | $8K | |
| 90756 | <1% | 469 | $8K | |
| 90661 | <1% | 3,330 | $7K | |
| 93295 | <1% | 323 | $7K | |
| 90620 | <1% | 150 | $7K | |
| 90680 | <1% | 3,468 | $7K | |
| 0013A | <1% | 249 | $7K | |
| 90710 | <1% | 406 | $7K | |
| L3260 | Surgical boot/shoe, each | <1% | 302 | $7K |
| 81025 | <1% | 1,295 | $7K | |
| 73502 | <1% | 167 | $7K | |
| 72050 | <1% | 122 | $6K | |
| 64494 | <1% | 136 | $6K | |
| 95805 | <1% | 14 | $6K | |
| 95018 | <1% | 54 | $6K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 513 | $6K |
| 92083 | <1% | 141 | $6K | |
| 92015 | Determination of refractive state | <1% | 5,420 | $6K |
| 99381 | <1% | 70 | $6K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 998 | $6K |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | <1% | 1,474 | $6K |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 1,038 | $6K |
| 57456 | <1% | 54 | $6K | |
| 92202 | <1% | 485 | $5K | |
| 64484 | <1% | 104 | $5K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,778 | $5K |
| 72040 | <1% | 142 | $5K | |
| 92020 | <1% | 258 | $5K | |
| 20985 | <1% | 134 | $5K | |
| 99307 | <1% | 350 | $5K | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 1,115 | $5K |
| 20550 | <1% | 112 | $5K | |
| 64495 | <1% | 90 | $5K | |
| J7324 | Hyaluronan or derivative, orthovisc, for intra-articular injection, per dose | <1% | 61 | $5K |
| 11730 | <1% | 59 | $4K | |
| 90716 | <1% | 652 | $4K | |
| 97014 | <1% | 350 | $4K | |
| 11311 | <1% | 46 | $4K | |
| 99349 | <1% | 172 | $4K | |
| 90707 | <1% | 722 | $4K | |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 27 | $4K |
| 72052 | <1% | 71 | $4K | |
| 77002 | <1% | 82 | $4K | |
| 99336 | <1% | 543 | $4K | |
| 68761 | <1% | 26 | $4K | |
| 82962 | <1% | 6,878 | $4K | |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 341 | $4K |
| 95250 | <1% | 57 | $4K | |
| 73110 | <1% | 79 | $4K | |
| 81002 | <1% | 2,942 | $3K | |
| 97802 | <1% | 468 | $3K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 684 | $3K |
| 90736 | <1% | 20 | $3K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 273 | $3K |
| 99337 | <1% | 121 | $3K | |
| 87070 | <1% | 526 | $3K | |
| 99152 | <1% | 108 | $3K | |
| 94760 | <1% | 3,256 | $3K | |
| 73140 | <1% | 66 | $3K | |
| 99241 | <1% | 56 | $3K | |
| 93280 | <1% | 142 | $3K | |
| 81003 | <1% | 10,223 | $3K | |
| 92226 | <1% | 160 | $3K | |
| 90732 | <1% | 30 | $3K | |
| 90636 | <1% | 26 | $2K | |
| 51798 | <1% | 149 | $2K | |
| 90473 | <1% | 190 | $2K | |
| 87634 | <1% | 209 | $2K | |
| 99217 | <1% | 81 | $2K | |
| 99242 | <1% | 28 | $2K | |
| 90696 | <1% | 426 | $2K | |
| 95251 | <1% | 106 | $2K | |
| 92553 | <1% | 59 | $2K | |
| 92286 | <1% | 126 | $2K | |
| 90744 | <1% | 2,140 | $2K | |
| 90700 | <1% | 976 | $2K | |
| 87081 | <1% | 479 | $2K | |
| 76512 | <1% | 51 | $2K | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 1,250 | $2K |
| 36415 | Collection of venous blood by venipuncture | <1% | 1,033 | $2K |
| 80061 | Lipid panel | <1% | 203 | $2K |
| 97162 | <1% | 27 | $2K | |
| 33016 | <1% | 16 | $2K | |
| 60100 | <1% | 12 | $2K | |
| 0134A | <1% | 67 | $1K | |
| 00813 | <1% | 13 | $1K | |
| 69209 | <1% | 113 | $1K | |
| 92133 | <1% | 44 | $1K | |
| 99253 | <1% | 15 | $1K | |
| 29580 | <1% | 25 | $1K | |
| 10040 | <1% | 19 | $1K | |
| 76514 | <1% | 107 | $1K | |
| 90713 | <1% | 479 | $1K | |
| 91322 | <1% | 20 | $1K | |
| 36470 | <1% | 16 | $1K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 33 | $1K |
| 93224 | <1% | 15 | $1K | |
| 90653 | <1% | 139 | $1K | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 106 | $995.17 |
| 90694 | <1% | 137 | $893.48 | |
| 00811 | <1% | 16 | $883.50 | |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 169 | $858.12 |
| 51741 | <1% | 92 | $836.03 | |
| 92201 | <1% | 44 | $827.97 | |
| 90632 | <1% | 13 | $817.65 | |
| 99383 | <1% | 12 | $815.69 | |
| 99051 | <1% | 1,590 | $813.73 | |
| G0008 | Administration of influenza virus vaccine | <1% | 1,295 | $810.91 |
| 91320 | <1% | 13 | $807.75 | |
| 36410 | <1% | 48 | $791.02 | |
| 87400 | <1% | 254 | $760.12 | |
| 90672 | <1% | 211 | $758.42 | |
| 73130 | <1% | 22 | $733.88 | |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 23 | $662.08 |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 13 | $658.38 |
| 90480 | <1% | 33 | $657.80 | |
| 94770 | <1% | 334 | $656.66 | |
| 96161 | <1% | 250 | $655.52 | |
| 90697 | <1% | 297 | $605.40 | |
| 99406 | <1% | 69 | $600.51 | |
| 99497 | <1% | 45 | $578.40 | |
| T1013 | Sign language or oral interpretive services, per 15 minutes | <1% | 88 | $555.00 |
| 11056 | <1% | 61 | $544.19 | |
| 90649 | <1% | 120 | $530.57 | |
| 91301 | <1% | 4,610 | $528.00 | |
| 90688 | <1% | 144 | $519.32 | |
| 97803 | <1% | 211 | $509.82 | |
| J1020 | Injection, methylprednisolone acetate, 20 mg | <1% | 241 | $504.65 |
| 97022 | <1% | 176 | $498.26 | |
| 73080 | <1% | 13 | $495.59 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 1,057 | $482.12 |
| 99335 | <1% | 104 | $478.38 | |
| 94070 | <1% | 14 | $473.68 | |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 68 | $471.86 |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 1,625 | $466.09 |
| 93016 | <1% | 28 | $399.56 | |
| 99459 | <1% | 22 | $391.45 | |
| 3074F | <1% | 19,193 | $382.00 | |
| 3078F | <1% | 17,642 | $375.00 | |
| 90648 | <1% | 523 | $357.64 | |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | <1% | 116 | $343.24 |
| 97035 | <1% | 170 | $321.44 | |
| 97032 | <1% | 115 | $278.39 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 419 | $271.77 |
| 99225 | <1% | 14 | $268.78 | |
| 96160 | <1% | 93 | $234.64 | |
| 90656 | <1% | 1,160 | $234.37 | |
| 93018 | <1% | 28 | $226.23 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 140 | $214.11 |
| 99024 | <1% | 3,802 | $213.00 | |
| 90658 | <1% | 47 | $186.40 | |
| 92132 | <1% | 12 | $178.00 | |
| 11720 | <1% | 27 | $177.91 | |
| 99347 | <1% | 13 | $163.45 | |
| 90685 | <1% | 206 | $154.70 | |
| 3079F | <1% | 6,095 | $151.00 | |
| 90474 | <1% | 12 | $148.18 | |
| 85610 | <1% | 57 | $143.03 | |
| 87807 | <1% | 39 | $119.88 | |
| 76937 | <1% | 16 | $110.11 | |
| 99050 | <1% | 15 | $84.85 | |
| 3075F | <1% | 2,094 | $75.00 | |
| J7510 | Prednisolone oral, per 5 mg | <1% | 29 | $73.78 |
| G0101 | Cervical or vaginal cancer screening; pelvic and clinical breast examination | <1% | 12 | $72.34 |
| 82947 | <1% | 31 | $64.55 | |
| 96380 | <1% | 48 | $61.28 | |
| V2020 | Frames, purchases | <1% | 6,286 | $60.00 |
| 3077F | <1% | 2,311 | $57.00 | |
| 99072 | <1% | 3,009 | $44.00 | |
| V2100 | Sphere, single vision, plano to plus or minus 4.00, per lens | <1% | 6,024 | $42.00 |
| 97760 | <1% | 30 | $41.91 | |
| G9016 | Smoking cessation counseling, individual, in the absence of or in addition to any other evaluation and management service, per session (6-10 minutes) [demo project code only] | <1% | 14 | $36.00 |
| 1126F | <1% | 425 | $31.00 | |
| 91307 | <1% | 90 | $30.00 | |
| 3045F | <1% | 136 | $27.00 | |
| 3061F | <1% | 252 | $24.00 | |
| G8427 | Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications | <1% | 4,175 | $21.00 |
| 3044F | <1% | 3,815 | $20.00 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 20 | $16.76 |
| G8510 | Screening for depression is documented as negative, a follow-up plan is not required | <1% | 25,261 | $15.20 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 12 | $11.00 |
| 1125F | <1% | 257 | $10.00 | |
| 3080F | <1% | 696 | $9.00 | |
| 3008F | <1% | 12,959 | $7.00 | |
| J2357 | Injection, omalizumab, 5 mg | <1% | 31 | $6.00 |
| 91300 | <1% | 103 | $5.00 | |
| 91313 | <1% | 61 | $5.00 | |
| 91306 | <1% | 27 | $2.00 | |
| 2024F | <1% | 14 | $1.00 | |
| G8417 | Bmi is documented above normal parameters and a follow-up plan is documented | 0% | 6,882 | $0.00 |
| G8752 | Most recent systolic blood pressure < 140 mmhg | 0% | 14,319 | $0.00 |
| 0502F | 0% | 698 | $0.00 | |
| 4004F | 0% | 292 | $0.00 | |
| 1124F | 0% | 4,775 | $0.00 | |
| G8482 | Influenza immunization administered or previously received | 0% | 2,769 | $0.00 |
| G8431 | Screening for depression is documented as being positive and a follow-up plan is documented | 0% | 1,229 | $0.00 |
| G8483 | Influenza immunization was not administered for reasons documented by clinician (e.g., patient allergy or other medical reasons, patient declined or other patient reasons, vaccine not available or other system reasons) | 0% | 2,516 | $0.00 |
| G8753 | Most recent systolic blood pressure >= 140 mmhg | 0% | 1,133 | $0.00 |
| 1160F | 0% | 43 | $0.00 | |
| 1033F | 0% | 156 | $0.00 | |
| 94799 | 0% | 64 | $0.00 | |
| V2203 | Spherocylinder, bifocal, plano to plus or minus 4.00d sphere, .12 to 2.00d cylinder, per lens | 0% | 616 | $0.00 |
| 1159F | 0% | 267 | $0.00 | |
| 2022F | 0% | 324 | $0.00 | |
| V2750 | Anti-reflective coating, per lens | 0% | 2,695 | $0.00 |
| 2028F | 0% | 27 | $0.00 | |
| 4040F | 0% | 17 | $0.00 | |
| 90655 | 0% | 29 | $0.00 | |
| J0897 | Injection, denosumab, 1 mg | 0% | 44 | $0.00 |
| 3288F | 0% | 45 | $0.00 | |
| 90630 | 0% | 12 | $0.00 | |
| G8420 | Bmi is documented within normal parameters and no follow-up plan is required | 0% | 1,858 | $0.00 |
| G8754 | Most recent diastolic blood pressure < 90 mmhg | 0% | 19,696 | $0.00 |
| 99000 | 0% | 812 | $0.00 | |
| 1036F | 0% | 10,294 | $0.00 | |
| G0009 | Administration of pneumococcal vaccine | 0% | 26 | $0.00 |
| V2103 | Spherocylinder, single vision, plano to plus or minus 4.00d sphere, .12 to 2.00d cylinder, per lens | 0% | 2,610 | $0.00 |
| G9903 | Patient screened for tobacco use and identified as a tobacco non-user | 0% | 389 | $0.00 |
| J3590 | Unclassified biologics | 0% | 347 | $0.00 |
| G8418 | Bmi is documented below normal parameters and a follow-up plan is documented | 0% | 256 | $0.00 |
| V2784 | Lens, polycarbonate or equal, any index, per lens | 0% | 5,102 | $0.00 |
| G8419 | Bmi documented outside normal parameters, no follow-up plan documented, no reason given | 0% | 503 | $0.00 |
| 92310 | 0% | 12 | $0.00 | |
| V2781 | Progressive lens, per lens | 0% | 135 | $0.00 |
| 1111F | 0% | 39 | $0.00 | |
| 1101F | 0% | 90 | $0.00 | |
| V2200 | Sphere, bifocal, plano to plus or minus 4.00d, per lens | 0% | 199 | $0.00 |
| V2299 | Specialty bifocal (by report) | 0% | 110 | $0.00 |
| S0620 | Routine ophthalmological examination including refraction; new patient | 0% | 304 | $0.00 |
| 2000F | 0% | 32 | $0.00 | |
| G8856 | Referral to a physician for an otologic evaluation performed | 0% | 14 | $0.00 |
| 0503F | 0% | 26 | $0.00 | |
| V2104 | Spherocylinder, single vision, plano to plus or minus 4.00d sphere, 2.12 to 4.00d cylinder, per lens | 0% | 104 | $0.00 |
| V2744 | Tint, photochromatic, per lens | 0% | 142 | $0.00 |
| G8755 | Most recent diastolic blood pressure >= 90 mmhg | 0% | 36 | $0.00 |
| 90673 | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBRAHMBHATT, GAURANG (CMO)
| Provider | Location | Paid |
|---|---|---|
| A.G. Dikengil, MD, PA | Lyndhurst, NJ | $1.03M |
| Riverside Pediatric Group, PC | Union City, NJ | $40K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.